

# Measures Under Consideration (MUC) Peer Reviewed Journal Article Template

## CY 2022 Final versus CY 2023 Final

**Burden impact:** The changes to this form do not reflect proposals in the CY 2024 Physician Fee Schedule (PFS) Final Rule for the Quality Payment Program. There are no impacts to burden as a result of these changes.

**Change #1:**

**Location:** Page 1: Document Title

**Reason for Change:**

Addition of year for clarity year over year.

**CY 2022 Final Rule text:**

MIPS Peer-Reviewed Journal Article Requirement Template

**CY 2023 Final Rule text:**

2023 MIPS Peer-Reviewed Journal Article Requirement Template

\*\*\*\*\*

**Change #2:**

**Location:** Page 1: Text under the first set of bullets starting with “Measure Title”

**Reason for Change:**

Removed to align with current CMS direction to no longer use this domain.

**CY 2022 Final Rule text:**

National Quality Strategy (NQS) Domain

**CY 2023 Final Rule text:**

This bullet was removed for 2023.

\*\*\*\*\*

**Change #3:**

**Location:** Page 1: Text under the first set of bullets starting with “Measure Title”

**Reason for Change:**

Updated to align current CMS direction for Meaningful Measures.

**CY 2022 Final Rule text:**

Meaningful Measure Area (MMA)

**CY 2023 Final Rule text:**

Meaningful Measures 2.0 Framework Domain

\*\*\*\*\*

**Change #4:**

**Location:** Page 1: First sub bullet under “Reliability/Validity”

**Reason for Change:**

Updated to align with the current fully developed definition.

**CY 2022 Final Rule text:**

Reliability Testing Results

**CY 2023 Final Rule text:**

Reliability Testing Results at the accountable entity level

\*\*\*\*\*

**Change #5:**

**Location:** Page 1: Second sub bullet under “Reliability/Validity”

**Reason for Change:**

Updated for clarity and to align with current fully developed definition.

**CY 2022 Final Rule text:**

Validity Testing Results, Clinician Sites

**CY 2023 Final Rule text:**

Face Validity Testing Results, Clinician Sites

\*\*\*\*\*

**Change #6**

**Location:** Page 1: New sub bullet under “Reliability/Validity”

**Reason for Change:**

Updated for clarity and to align with current fully developed definition.

**CY 2022 Final Rule text:**

*This bullet is new for 2023.*

**CY 2023 Final Rule text:**

Empiric Validity Testing Results at the accountable entity level

\*\*\*\*\*

**Change #7:**

**Location:** Page 1: New sub bullet under “Reliability/Validity”

**Reason for Change:**

Updated for clarity and to align with current fully developed definition.

**CY 2022 Final Rule text:**

*This bullet is new for 2023.*

**CY 2023 Final Rule text:**

Data Element/Patient Encounter Level Testing

\*\*\*\*\*

**Change #:8**

**Location:** Page 2: New sub bullet under “Other Information”

**Reason for Change:**

Updated for clarity and to align with the current fully developed definition.

**CY 2022 Final Rule text:**

*This bullet is new for 2023.*

**CY 2023 Final Rule text:**

Specify measure stage of development.

\*\*\*\*\*

**Change #9:**

**Location:** Page 2: New sub bullet under “Other Information” and two additional sub bullets

**Reason for Change:**

Updated for clarity and to align with current fully developed definition.

**CY 2022 Final Rule text:**

*These bullets are new for 2023.*

**CY 2023 Final Rule text:**

o For Patient Reported Outcome Performance Measures:

- The survey or tool has been tested and does not require modifications based on results?

- Patient/encounter level testing for each critical data element does not require changes to the tool base on the results?

\*\*\*\*\*

**Change #10:**

**Location:** Page 2: Bullet under “Endorsement”

**Reason for Change:**

Updated to current language.

**CY 2022 Final Rule text:**

Provide the National Quality Forum (NQF) endorsement status (and NQF measure identifier) and/or other endorsing body (If the measure is only endorsed for paper records, please note endorsement for only the data source being submitted.).

**CY 2023 Final Rule text:**

Provide the Consensus-Based Entity (CBE) endorsement status (i.e., National Quality Forum (NQF)) (and CBE ID) and/or other endorsing body (If the measure is only endorsed for paper records, please note endorsement for only the data source being submitted.).

\*\*\*\*\*

**Change #11:**

**Location:** Page 2: Second bullet under “Summary”

**Reason for Change:**

Updated for clarity.

**CY 2022 Final Rule text:**

Importance to MIPS or other CMS programs.

**CY 2023 Final Rule text:**

Relevance to MIPS or other CMS programs.